Clinical Trial Update: Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating Lomecel-B (Longeveron) for vaccine-specific antibody response in subjects with aging frailty; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aging Frailty

Drugs mentioned

• Lomecel-B (bone marrow-derived mesenchymal stromal cells)

Snippet

Sponsor: Longeveron Inc. | Conditions: Aging Frailty | Phase 1, Phase 2 | Status: COMPLETED